奥沙利铂联合卡培他滨或替吉奥对晚期结肠癌患者mi R-21表达的影响及临床疗效评估

Effect of Oxaliplatin Combined with Capecitabine or Tegafur on miR-21Expression in Patients with Advanced Colon Cancer and Its Clinical Efficacy

目的晚期结肠癌患者通过奥沙利铂与卡培他滨或者替吉奥进行联合治疗,对两种不同方法治疗后的治疗效果进行比较。方法该次研究,从该院在2015年5月-2018年5月期间内收治的晚期结肠癌患者中随机抽取出105例患者,将所有患者当成该次研究的研究对象并按照随机化方法分成两组;一组患者通过奥沙利铂与替吉奥进行联合治疗,叫做实验组(n=55);一组患者通过卡培他滨与奥沙利铂进行联合治疗,叫做对照组(n=50)。对两组患者的血清白介素-2(IL-2)、肿瘤坏死因子-α(TNF-α)以及mi R-21的水平以及治疗总有效率、化疗不良反应发生情况进行比较,对两种方法的临床效果进行评价。结果治疗后,实验组患者血清IL-2、TNF-α稍低于治疗前水平,差异无统计学意义(P>0.05);对照组患者血清IL-2、TNF-α低于治疗前水平,差异有统计学意义(P<0.05);实验组血浆miR-21水平低于对照组,差异有统计学意义(P<0.05)[实验组为(3.13±0.32),对照组为(6.49±0.41);实验组总有效率高于对照组,实验组为65.5%,对照组为42.0%,而不良反应总发生率低于对照组,实验组为34.5%,对照组为74.0%,差异有统计学意义(χ^2=15.663、15.429,P<0.05)。结论晚期结肠癌患者的治疗中,奥沙利铂联合替吉奥在调节患者免疫水平、改善临床疗效、抑制肿瘤进展优于奥沙利铂联合卡培他滨,且不良反应低,其机制可能是通过调节肿瘤患者血液中血清白介素-2(IL-2),肿瘤坏死因子-α(TNF-α)及mi R-21水平来实现的。

Objective To compare the therapeutic effects of two different methods after treatment with oxaliplatin or capecitabine or tegafur in patients with advanced colon cancer. Methods In this study, the authors randomly selected105 patients from patients with advanced colon cancer who were admitted to the hospital from May 2015 to May 2018.All patients were included in the study and followed. The randomized method was used to divide the two groups;one group of patients was treated with oxaliplatin and tigeo, called the experimental group(n=55);a group of patients was treated with capecitabine and oxaliplatin, called control group(n=50). The levels of serum interleukin-2(IL-2), tumor necrosis factor-α(TNF-α), and miR-21 were compared between the two groups, as well as the total effective rate of treatment and the occurrence of chemotherapy side effects. Clinical effects were evaluated. Results After treatment,serum IL-2 and TNF-α in the experimental group were slightly lower than the pre-treatment levels, the difference was not statistically significant(P>0.05);serum IL-2 and TNF-α in patients with capecitabine, and the difference was statistically significant(P<0.05). The plasma miR-21 level in the experimental group was lower than that in the control group(P <0.05). The experimental group was(3.13±0.32). The control group was(I6.49±0.41);the total effective rate of the experimental group was higher than that of the control group, 65.5% in the experimental group, 42.0% in the control group, and the total incidence of adverse reactions was lower than that of capecita, 34.5% in the experimental group, 74.0% in the control group,the difference was statistically significant(χ^2=15.663,15.429,P<0.05). Conclusion In the treatment of patients with advanced colon cancer, oxaliplatin combined with tiggio is better than oxaliplatin combined with capecitabine in regulating immune level, improving clinical efficacy and inhibiting tumor progression, and its mechanism is low. It may be achieved by regulating serum interleukin-2(IL-2), tumor necrosis factor-α(TNF-α) and miR-21 levels in the blood of tumor patients.